Dasatinib has shown significant efficacy in treating Ph+ CML and ALL, particularly in patients who have not responded to previous treatments. Its ability to target multiple tyrosine kinases makes it a versatile option in the cancer treatment arsenal. Many patients experience prolonged remission, significantly improving their quality of life.
